搜索
Neuronetics Inc
STIM添加自选
1.410USD
+0.060+4.44%
收盘 07/02, 13:00（美东）报价延迟15分钟
98.11M总市值
亏损市盈率 TTM
关键数据
1.370今开
1.410最高
617.61K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.89%换手率
1.350昨收
1.335最低
604.24K成交额
亏损市盈率静
7.40市净率
0.00%股息率 TTM
-27.84%ROA
4.84952周最高
0.61量比
-43.71M净利润
69.58M总股本
-0.5402每股收益TTM
1.07Beta
-152.36%ROE
0.80052周最低
5.56%振幅
46.89%毛利率
98.11M总市值
-0.47回报/风险
6.11%风险率
TradingKey Neuronetics Inc股票评分
单位: USD 更新时间: 2026-07-01操作建议
Neuronetics Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名93/204位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.33。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Neuronetics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Neuronetics Inc亮点
亮点风险
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
业绩高增长
公司营业收入稳步增长，连续3年增长109.06%
利润高增长
公司净利润处于行业前列，最新年度总收入149.16M美元
估值合理
公司最新PE估值-2.50，处于3年历史合理位
机构减仓
最新机构持股47.87M股，环比减少13.05%
活跃度降低
近期活跃度降低，过去20天平均换手率-0.02
分析师目标
根据
3
位分析师
买入
评级
4.333
目标均价
+218.63%
涨幅空间
Neuronetics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Neuronetics Inc简介
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
公司代码STIM
公司Neuronetics Inc
CEOMr. Keith J. Sullivan
网址https://neurostar.com/neuronetics/
相关品种
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%热门品种
常见问题
Neuronetics Inc(STIM)的当前股价是多少？
Neuronetics Inc(STIM)的当前股价是 1.35。
Neuronetics Inc的股票代码是什么？
Neuronetics Inc的股票代码是STIM。
Neuronetics Inc股票的52周最高点是多少？
Neuronetics Inc股票的52周最高点是4.85。
Neuronetics Inc股票的52周最低点是多少？
Neuronetics Inc股票的52周最低点是0.80。
Neuronetics Inc的市值是多少？
Neuronetics Inc的市值是93.94M。
现在Neuronetics Inc(STIM)的股票是买入、持有还是卖出？
根据分析师评级，Neuronetics Inc(STIM)的总体评级为买入，目标价格为4.33。
Neuronetics Inc(STIM)股票的每股收益（EPS TTM）是多少
Neuronetics Inc(STIM)股票的每股收益（EPS TTM）是-0.59。